工程免疫：癌症新抗原疫苗的细菌递送。

IF 13.1 1区医学 Q1 IMMUNOLOGY

Trends in Immunology Pub Date : 2024-11-27 DOI:10.1016/j.it.2024.11.007

Christopher D Johnston, Jennifer A Wargo

{"title":"工程免疫：癌症新抗原疫苗的细菌递送。","authors":"Christopher D Johnston, Jennifer A Wargo","doi":"10.1016/j.it.2024.11.007","DOIUrl":null,"url":null,"abstract":"In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to deliver cancer neoantigen payloads, stimulating antigen-specific CD4+ and CD8+ T cells and mediating antitumor immunity in preclinical models of colorectal cancer and melanoma.","PeriodicalId":54412,"journal":{"name":"Trends in Immunology","volume":" ","pages":""},"PeriodicalIF":13.1000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Engineering immunity: bacterial delivery of cancer neoantigen vaccines.\",\"authors\":\"Christopher D Johnston, Jennifer A Wargo\",\"doi\":\"10.1016/j.it.2024.11.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to deliver cancer neoantigen payloads, stimulating antigen-specific CD4+ and CD8+ T cells and mediating antitumor immunity in preclinical models of colorectal cancer and melanoma.\",\"PeriodicalId\":54412,\"journal\":{\"name\":\"Trends in Immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":13.1000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.it.2024.11.007\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.it.2024.11.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在抗击癌症的斗争中，研究人员正在探索利用工程细菌作为活体药物。Redenti及其同事证明，大肠杆菌Nissle 1917（EcN）可被设计成传递癌症新抗原有效载荷，刺激抗原特异性CD4+和CD8+T细胞，并在结直肠癌和黑色素瘤临床前模型中介导抗肿瘤免疫。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Engineering immunity: bacterial delivery of cancer neoantigen vaccines.

In the battle against cancer, researchers are exploring the use of engineered bacteria as living medicines. Redenti and colleagues demonstrate that Escherichia coli Nissle 1917 (EcN) can be engineered to deliver cancer neoantigen payloads, stimulating antigen-specific CD4⁺ and CD8⁺ T cells and mediating antitumor immunity in preclinical models of colorectal cancer and melanoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in Immunology 医学-免疫学

CiteScore

25.10

自引率

0.60%

发文量

130

审稿时长

6-12 weeks

期刊介绍： Trends in Immunology serves as a vital platform for tracking advancements across various areas of immunology, offering concise reviews and hypothesis-driven viewpoints in each issue. With additional sections providing comprehensive coverage, the journal offers a holistic view of immunology. This broad perspective makes it an invaluable resource for researchers, educators, and students, facilitating the connection between basic and clinical immunology. Recognized as one of the top monthly review journals in its field, Trends in Immunology is highly regarded by the scientific community.